Octaplas Market Report 2026

Octaplas Market Overview

• The Octaplas market growth in the historic period has been driven by expansion of surgical and trauma care services, increasing need for large-volume plasma transfusion • Market expansion is supported by increasing focus on transfusion safety, expansion of emergency and critical care infrastructure • Growth Driver: Impact Of Rising Blood Disorders On The Market Growth • Market Trend: Advancements In Plasma-based Therapies For Bleeding Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Octaplas Market?

Octaplas is a blood plasma product used for patients requiring large-volume plasma transfusions. It is a pathogen-reduced, standardized liquid preparation derived from pooled human plasma, providing essential clotting factors and proteins. Octaplas are often utilized in surgeries, trauma care, and conditions with significant coagulopathy. The main indications of octaplas are hematology, immunology, critical care, pulmonology, and neurology. Hematology is a branch of medicine concerned with the diagnosis and treatment of blood disorders, including anemia, clotting disorders, and leukemia. Octaplas are used in hematology to replace plasma proteins and restore clotting factors in patients requiring urgent surgical intervention or suffering from significant bleeding. These are distributed through several distribution channels, such as online sales and distributors, and are used in hospitals and clinics, clinical research laboratories, and blood banks.

What Is The Octaplas Market Growth Forecast?

The growth in the forecast period can be attributed to increasing focus on transfusion safety, expansion of emergency and critical care infrastructure, rising adoption in complex surgeries, advancements in plasma pathogen inactivation, growing investments in blood product standardization. Major trends in the forecast period include increasing adoption of pathogen-reduced plasma products, rising use in trauma and critical care, expansion of standardized plasma transfusions, improved safety in coagulation management, growing demand for ready-to-use plasma.

Global Octaplas Market Segmentation

1) By Indication: Hematology, Immunology, Critical Care, Pulmonology, Neurology 2) By Distribution Channel: Online Sales, Distributors 3) By End User: Hospitals And Clinics, Clinical Research Laboratories, Blood Banks

What Are The Drivers Of The Octaplas Market?

The rise in blood disorders is expected to propel the growth of the octaplas market going forward. Blood disorders are medical conditions that impact the various components of blood, such as red blood cells, white blood cells, platelets, and plasma. The rise in blood disorders is due to increasing environmental pollutants, genetic predispositions, lifestyle changes, and improved diagnostic techniques. Octaplas supports patient care by providing human plasma for the treatment of coagulopathies and supporting critically ill patients. For instance, in May 2024, according to the Leukaemia Foundation, an Australia-based national charity organization, in 2022, an estimated 19,403 Australians were diagnosed with blood cancers, averaging 53 cases daily. About 135,000 people are currently living with blood cancers, a number projected to exceed 275,000 by 2035. Therefore, the rise in blood disorders is driving the growth of the octaplas industry. The increase in personalized medicine has contributed to the growth of the octaplas market going forward. Personalized medicine supports healthcare providers in creating tailored treatment plans and making informed treatment choices by utilizing a patient's genetic information to understand their specific disease. The rise in personalized medicine is driven by advancements in genetic research and technology, enabling tailored treatments that improve patient outcomes. Personalized medicine in octaplas helps tailor plasma-based therapies to individual patient needs, enhancing treatment outcomes for conditions like bleeding disorders and immune deficiencies. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the increasing personalized medicine is expected to drive the growth of the octaplas industry.

Key Players In The Global Octaplas Market

Major companies operating in the octaplas market are Octapharma AG

Global Octaplas Market Trends and Insights

The key trends in the Octaplas market focus on advancements in blood plasma therapy, such as lyophilised pathogen-inactivated plasma pre-hospital transfusion authorization to enhance rapid emergency-care readiness by enabling safe, stable, and immediately deployable plasma administration in critical pre-hospital environments. Lyophilised pathogen-inactivated plasma pre-hospital transfusion authorization refers to the formal regulatory approval granted for a freeze-dried, solvent/detergent-treated plasma formulation intended for emergency use outside hospital settings. For instance, in February 2023, Octapharma AG, a Switzerland-based pharmaceutical company, announced that its established product, octaplasLG, received approval from European medical authorities for a new lyophilized formulation. This new version, which comes as a powder and solvent for infusion, offers improved treatment options for pre-hospital and emergency situations. OctaplasLG is a pharmaceutical-grade human plasma product that meets standardized quality requirements and boasts a unique pathogen safety profile. This safety is achieved through rigorous processes for pathogen elimination and inactivation, including donor screening, immunoneutralization, solvent or detergent treatment, and prion reduction using ligand affinity chromatography.

Regional Insights

North America was the largest region in the octaplas market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Octaplas Market?

The octaplas market consists of sales of infusion sets, plasma storage bags, sterile needles, syringes, IV connectors, and tubing. Value in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Octaplas Market Report 2026?

The octaplas market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the octaplas industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.